GNRH1 and posterior cortical atrophy: The first meta-analysis[11] including 27 trials which focused on metastatic (88%) and locally advanced (12%) PCa patients concluded that maximal androgen blockade [MAB] (OT + AA or CAB or OT + CPT) improved the 5-year survival by about 2% or 3% compared to androgen suppression alone [AS] (OT or LHRH agonist).